Diatech Pharmacogenetics and Horizon Diagnostics Reach Distribution Deal for Molecular Reference Standards

Two leading companies in the diagnosis united in the fight against cancer.

Myriapod is the next generation system that Diatech is introducing in the market, using mass spectrometry associated with single base extension on Sequenom platform. Currently the system has been adopted by Azienda Ospedaliera Universitaria Pisana, Istituto Scientico ROmagnolo per lo studio e il trattamento del Cancro IRCCS Meldola (FC), Ospedale Maggiore Policlinico IRCCS Ca ‘Granda, Istituto Europeo di Oncologia, Azienda Ospedaliera Universitaria Udine and Ospedale Sant’Andrea in Rome.

Other 12 other centers of national importance it will be equipped soon.

Fabio Biondi, president of the Diatech Pharmacogenetics, said: “We are proud to partner with Horizon Discovery. Through this agreement we will be able to enhance the system Myriapod. The synergy between the two companies – says Fabio Biondi – will provide centers who daily face the battle against cancer, a system capable of determining with great precision and accuracy possible drug therapy. This strategy will improve the quality of life of patients with significant savings in drug costs without ‘disturbing’ the-board cuts health care costs that, besides being useless, is an anachronism”.

Horizon Discovery is based in Cambridge and is focused on translational genomics, genome editing, and personalized medicine. Provides standard molecular able to speed up the search for the development of oncology drugs of last generation. Within the scientific board, outstanding figures of international importance, so much so that now, though newly established, has received prestigious awards including the Queen’s Award for Enterprise (2012), one for the business year 2011 from the East of England Business Awards and Bioscience Company of the Future Award (2010). Horizon Discovery has strategic partnerships with UK NEQAS (United Kingdom National External Quality Assessment Service) and EMQN (European Molecular Genetics Quality Network) and has collaborated with pharmaceutical companies among the most important in the world in the development of anticancer therapies.

Diatech Pharmacogenetics is the leader in the Italian market of predictive tests required in cancer therapy. Its products are developed in is own research laboratories and now used in more than 40 Italian centers.